Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

SRL-172 associated with significantly improved survival in SCLC patients

March 28, 2000

Phase I clinical study to begin with Reolysin as cancer treatment

March 27, 2000

FDA grants orphan drug status to Zadaxin for treatment of liver cancer

March 24, 2000

Phase I study of AltaRex's BrevaRex MAb completed

March 22, 2000

StressGen initiates phase II study with HspE7 in high-grade cervical dysplasia

March 22, 2000

FDA's ODAC recommends approval of Mylotarg for relapsed AML

March 21, 2000

Picower Institute presents new immunotherapeutic anticancer agents

March 17, 2000

Antisoma takes up another product from ICRF for clinical development

March 17, 2000

Low-dose M-Vax shows promise in stage III metastatic melanoma

March 17, 2000

Seattle Genetics updates MAb program

March 17, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...